These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28356715)

  • 1. Clinical potential of SLAMF7 antibodies - focus on elotuzumab in multiple myeloma.
    Friend R; Bhutani M; Voorhees PM; Usmani SZ
    Drug Des Devel Ther; 2017; 11():893-900. PubMed ID: 28356715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.
    Palumbo A; Sonneveld P
    Expert Rev Hematol; 2015 Aug; 8(4):481-91. PubMed ID: 26070331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elotuzumab for the treatment of multiple myeloma.
    Moreau P; Touzeau C
    Future Oncol; 2014 May; 10(6):949-56. PubMed ID: 24941981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma.
    Campbell KS; Cohen AD; Pazina T
    Front Immunol; 2018; 9():2551. PubMed ID: 30455698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elotuzumab: First Global Approval.
    Markham A
    Drugs; 2016 Mar; 76(3):397-403. PubMed ID: 26809244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elotuzumab for the treatment of multiple myeloma.
    Wang Y; Sanchez L; Siegel DS; Wang ML
    J Hematol Oncol; 2016 Jul; 9(1):55. PubMed ID: 27417553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma.
    Pazina T; James AM; Colby KB; Yang Y; Gale A; Jhatakia A; Kearney AY; Graziano RF; Bezman NA; Robbins MD; Cohen AD; Campbell KS
    Cancer Immunol Res; 2019 Oct; 7(10):1633-1646. PubMed ID: 31431433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.
    Grosicki S; Barchnicka A
    Expert Rev Hematol; 2016 Jul; 9(7):621-8. PubMed ID: 27322214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
    Offidani M; Corvatta L
    Future Oncol; 2018 Feb; 14(4):319-329. PubMed ID: 29091475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of SLAMF7 in multiple myeloma: impact on therapy.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
    Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
    Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
    Iida S; Nagai H; Kinoshita G; Miyoshi M; Robbins M; Pandya D; Bleickardt E; Chou T
    Int J Hematol; 2017 Mar; 105(3):326-334. PubMed ID: 27848182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Laubach J; Richardson P
    Expert Opin Biol Ther; 2013 Dec; 13(12):1731-40. PubMed ID: 24151843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of Action and Clinical Development of Elotuzumab.
    Ritchie D; Colonna M
    Clin Transl Sci; 2018 May; 11(3):261-266. PubMed ID: 29272564
    [No Abstract]   [Full Text] [Related]  

  • 17. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
    Zamagni E; Tacchetti P; Pantani L; Cavo M
    Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
    Veillette A; Guo H
    Crit Rev Oncol Hematol; 2013 Oct; 88(1):168-77. PubMed ID: 23731618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Drug Saf; 2017 Feb; 16(2):237-245. PubMed ID: 28060563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of elotuzumab in the treatment of relapsed or refractory multiple myeloma.
    Comeau JM; Kelly K; Jean GW
    Am J Health Syst Pharm; 2018 Jan; 75(2):55-66. PubMed ID: 29317395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.